Antiviral agent. Inhibits IMPDH2, which interacts with SARS-CoV-2 Nsp14; may also inhibit viral RNA polymerase. ordon et al. bioRxiv, Mar 23 2020; https://doi.org/10.1101/2020.03.22.002386; Liu et al. ACS Cent. Sci., 6:315-331, Mar 12 2020, https://doi.org/10.1021/acscentsci.0c00272; Wang et al. Cell Res 30:269–271, Feb 4 2020, https://doi.org/10.1038/s41422-020-0282-0.
- Datasheet: view or download
- Applications:Approved drug (U.S.) that could be repurposed
Biochemicals & reagents
1) Bougie and Bisaillon (2003), Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase; J. Biol. Chem. 278 52471 2) Crotty et al. (2000), The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen; Nat.Med. 6 1375 3) Zhou et al. (2003), The effect of ribavirin and IMPDH inhibitos on hepatitis C virus subgenomic replicon RNA; Virology 310 333 4) Couee and Tipton (1990), Inhibition of ox brain glutamate by perphenazine; Biochem. Pharmacol. 39 1167
Ribavirin is a clinically relevant antiviral medication for Hepatitis C, viral hemorrhagic fevers and other RNA and DNA viruses. The exact mechanism of its antiviral activity is uncertain but several proposals include inhibition of viral polymerase (1), RNA mutagenesis (2) and inosine monophosphate dehydrogenase (IMPDH) inhibition (3).